GL1X · GenesisL1 explorer

MolNFT v1 · #127397 · protein

Crystal structure of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds

5MVD · Dihydroorotate dehydrogenase (quinone), mitochondrial: “Crystal structure of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole…”. X-ray diffraction, 4 ligands (FMN, ORO, U91), 4 pockets (best…

PDB
5MVD
Type
protein
Length
348 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Dihydroorotate dehydrogenase (quinone), mitochondrial
EC
1.3.5.2
UniProt
Q02127
Ligands
FMN, ORO, U91, CL
Pockets
4 · best druggability 0.83

Structure

x-ray diffraction · 1 distinct chain · 47% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ADihydroorotate dehydrogenase (quinone), mitochondrial (EC 1.3.5.2)protein34847% helix, 17% strandQ02127

Ligands and binding sites

  • FMN · Flavin mononucleotide · ligand · chains A
  • ORO · Orotic acid · ligand · chains A
  • U91 · 1,5-dimethyl-3-oxidanyl-~{N}-[2,3,5,6-tetrakis(fluoranyl)-4-phenyl-phenyl]pyrazole-4-carboxamide · ligand · chains A
  • CL · Chloride ion · ion · 3 copies · chains A
  • ACT · Acetate ion · additive · 2 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14580.830.9068FMN, ORO, U91
2820.420.8019ACT
31220.400.7421empty
4500.250.7314empty

Compared structures

  • 5MVD · Crystal structure of potent human Dihydroorotate Dehydrogenase inhibitors based on… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.